

4th International Meeting on Cancer Molecular Markers

from discovery to clinical practice

Final Agenda

Co-chairs:

Daniel F. Hayes, M.D., University of Michigan, Ann Arbor, United States

Fred C.G.J. Sweep, Ph.D., Radboud University Nijmegen Medical Center, The Netherlands

Organizing Committee:

Massimo Gion, M.D., General Regional Hospital, Venice, Italy

Nadia Harbeck, M.D., Technical University of Munich, Germany

Robert B. Jenkins, M.D., Ph.D., Mayo Clinic, Rochester, Minnesota, United States

Tracy Lively, Ph.D., National Cancer Institute, Bethesda, Maryland, United States

Martine Piccart, M.D., Ph.D., Jules Bordet Institute, Brussels, Belgium

Richard Schilsky, M.D., University of Chicago, Illinois, United States

Friday, September 8, 2006

- 1:00 p.m. **Welcome and Introductions**
Daniel F. Hayes, M.D.
Fred C.G.J. Sweep, Ph.D.
Martine Piccart, M.D., Ph.D., EORTC President
James Doroshow, M.D., National Cancer Institute, Bethesda, Maryland, United States
- 1:15 p.m. **Scientific Session 1: Stem Cells as Markers and Targets of Therapy**
U.S. Moderator: *Max S. Wicha, M.D., University of Michigan, Ann Arbor, United States*
European Moderator: *Giovanni Morrone, M.D., University of Catanzaro 'Magna Græcia,' Italy*
- Keynote Lecture: "Cancer Stem Cells: Diagnostic and Therapeutic Promises"**
Max S. Wicha, M.D.
- 2:00 p.m. **"Stem Cells in B Cell Malignancies"**
William Matsui, M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- 2:25 p.m. **"Stem Cells from Prostate Cancer: A New Paradigm for Cancer Therapy"**
Norman J. Maitland, Ph.D., University of York, United Kingdom
- 2:50 p.m. **Session Wrap-up**
Giovanni Morrone, M.D.
- 3:00 p.m. Break

- 3:30 p.m. **Scientific Session 2: Assessment of Minimal Detectable Disease**
 U.S. Moderator: *G. Thomas Budd, M.D., Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States*
 European Moderator: *Klaus Pantel, M.D., University Medical Center Hamburg-Eppendorf, Germany*
- Keynote Lecture: “Detection and Characterization of Disseminated Tumor Cells in Cancer Patients: Current State and Future Developments”**
Klaus Pantel, M.D.
- 4:15 p.m. **“Minimal Detectable Disease in Sentinel Lymph Nodes of Solid Tumor Patients”**
Steven C. Shivers, Ph.D., Lakeland Regional Cancer Center, Lakeland, Florida, United States
- 4:40 p.m. **“Clinical Relevance of Circulating Tumor Cell Detection in Patients with Solid Tumors”**
G. Thomas Budd, M.D.
- 5:05 p.m. **“MRD Detection in Haematological Malignancies”**
Michael Kneba, M.D., University Hospital Schleswig-Holstein, Kiel, Germany
- 5:30 p.m. **Poster Session and Exhibits**
- 6:30 p.m. **Optional Opening Banquet**

Saturday, September 9, 2006

- 8:00 a.m. **Scientific Session 3: Pharmacogenomics**
 U.S. Moderator: *David Flockhart, M.D., Ph.D., Indiana University School of Medicine, Indianapolis, United States*
 European Moderator: *Irma Meijerman, Ph.D., Utrecht University, The Netherlands*
- Keynote Lecture: “Pharmacogenomics: Germ Line Markers for Individualization of Therapy”**
Mary Relling, Pharm.D., St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
- 8:30 a.m. **“Have We Made Progress in the Implementation of Pharmacogenomics in Cancer Therapy?”**
Howard McLeod, Pharm.D., University of North Carolina, Chapel Hill, United States
- 8:50 a.m. **“Pharmacogenetics of Drug Transporters in Chemotherapeutic Treatment”**
Tessa Bosch, Ph.D., Pharm.D., Medical Center Rijnmond-Zuid, Rotterdam, The Netherlands
- 9:10 a.m. **“Pharmacogenetics of the Nuclear Receptors PXR and CAR and Their Role in Oncology”**
Irma Meijerman, Ph.D.

- 9:30 a.m. **“Cytochrome P450 3A5 Polymorphisms and Chemotherapy”**
Jamie Renbarger, M.D., Indiana University School of Medicine, Indianapolis, United States
- 9:50 a.m. **“Pharmacogenomics in Endocrine Treatment for Breast Cancer”**
David Flockhart, M.D., Ph.D.
- 10:10 a.m. **Poster Viewing and Exhibits**
- 11:00 a.m. **Selected Oral Poster Presentations**
 U.S. Moderator: *Daniel F. Hayes, M.D.*
 European Moderator: *Fred C.G.J. Sweep, Ph.D.*
- 11:15 a.m. • **“CK19/P-cadherin Ratio is a Strong Prognostic Indicator of Clinical Outcome in Early Stage Non-small Cell Lung Cancer (NSCLC) Adenocarcinoma Patients”**
Michael Mitas, Ph.D., Medical University of South Carolina, Charleston, United States
- 11:30 a.m. • **“Transcription Factor NFIB Represents a Potential Novel Therapeutic Target for Er-negative Breast Cancer”**
Fabrice Andre, M.D., University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
- 11:45 a.m. • **“Single Sample Prediction of Breast Cancer Biological Subtypes from Formalin-fixed Paraffin-embedded Tissue Using Real-time Quantitative RT-PCR”**
Michael Mullins, Ph.D., University of Utah School of Medicine, Salt Lake City, United States
- 12:00 p.m. • **“Pharmacogenetics and Breast Cancer Treatment Outcomes: Results on Oxidative Stress Related Genotypes (MPO, MNSOD) from a Southwest Oncology Group Trial (S8897)”**
Ji-Yeob Choi, Ph.D., Roswell Park Cancer Institute, Buffalo, New York, United States
- 12:15 p.m. • **“ALDH1: A Marker of Human Breast Cancer Stem Cells?”**
Christophe Ginestier, Ph.D., University of Michigan, Ann Arbor, United States
- 12:30 p.m. • **“Single Cell Profiling of STAT5-P Expression: A Surrogate Marker of Imatinib Sensitivity In CML Cells and Tumors”**
Maria Cruz Marin, Ph.D., Spanish National Cancer Centre, Madrid, Spain
- 12:30 p.m. Lunch

- 2:00 p.m. **Scientific Session 4: Proteomics**
U.S. Moderator: *O. John Semmes, Ph.D., Eastern Virginia Medical School, Norfolk, United States*
European Moderator: *Julio E. Celis, Ph.D., Institute of Cancer Biology, Danish Cancer Society and Danish Centre for Translational Breast Cancer Research, Copenhagen, Denmark*
- Keynote Lecture: “Focusing Proteomics to the Task of Biomarker Discovery”**
O. John Semmes, Ph.D.
- 2:45 p.m. **“TIMP-1 as a New Cancer Biomarker: From Bench to Bed and Back Again”**
Nils Brünner, M.D., D.M.Sc., Royal Veterinary and Agriculture University, Frederiksberg, Denmark
- 3:15 p.m. **“Molecular Imaging of Proteins Using Mass Spectrometry”**
Michelle L. Reyzer, Ph.D., Vanderbilt University, Nashville, Tennessee, United States
- 3:45 p.m. **Session Wrap-up**
Julio E. Celis, Ph.D.
- 3:55 p.m. **Poster Viewing and Exhibits**
- 5:30 p.m. **Free Time; Faculty Banquet**

Sunday, September 10

- 8:00 a.m. **Plenary Session: Path to the Clinic for Multigene Signatures: The Breast Cancer Paradigm**
U.S. Moderator: *Richard L. Schilsky, M.D.*
European Moderator: *Martine Piccart, M.D., Ph.D.*
- Keynote Lecture: “Molecular Profiling of Breast Cancer: Reading the Handwriting on the Wall”**
Martine Piccart, M.D., Ph.D.
- 8:30 a.m. **Molecular Signatures to Guide Post-operative Adjuvant Treatment**
- **The U.S. TAILORRx Trial**
Joseph Sparano, M.D., Albert Einstein College of Medicine, Bronx, New York, United States
- 8:45 a.m. • **The BIG-1 MINDACT Trial**
Emiel J.Th. Rutgers, M.D., Ph.D., The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 9:00 a.m. **“Molecular Signatures of Response to Therapy”**
Lajos Pusztai, M.D., D.Phil., University of Texas M.D. Anderson Cancer Center, Houston, United States

- 9:15 a.m. **“Multigene Signatures for Breast Cancer Management: Pandora’s Box or a Jewelry Box?”**
- **The Statistician’s Point of View**
Lisa McShane, Ph.D., National Cancer Institute, Bethesda, Maryland, United States
- 9:35 a.m. • **The Clinician’s Point of View**
Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center, New York, United States
- 9:55 a.m. **Roundtable Discussion**
Leader: Richard L. Schilsky, M.D.
- Participants:*
Jan G.M. Klijn, M.D., Ph.D., Erasmus Medical Center, Rotterdam, The Netherlands
Lisa McShane, Ph.D., National Cancer Institute, Bethesda, Maryland, United States
Stefan Michiels, Ph.D., Institute Gustave Roussy, Villejuiff, France
Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center, New York, United States
David Ransohoff, M.D., University of North Carolina, Durham, United States
Ann D. Thor, M.D., University of Colorado Health Sciences Center, Denver, United States
Laura Van’t Veer, Ph.D., The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 10:30 a.m. **Closing Comments and Wrap-up**
Daniel F. Hayes, M.D.
Fred C.G.J. Sweep, Ph.D.